Chemical Nameinebilizumab-cdon
Dosage FormInjection (intravenous; 100 mg/10 mL)
Drug ClassMonoclonal antibodies
CompanyViela Bio
Approval Year2020


  • Indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
Last updated on 12/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Uplizna (inebilizumab-cdon) Prescribing Information.2020Viela Bio, Inc. Gaithersburg, MD